| Avacta data AACR underline AVA6103 profile | 21-Apr-2026 | 07:00 | RNS |
| Q1 2026 Business Update | 09-Apr-2026 | 07:00 | RNS |
| First patient treated in Phase 1 trial of AVA6103 | 31-Mar-2026 | 07:00 | RNS |
| Result of Oversubscribed Fundraise | 27-Mar-2026 | 07:00 | RNS |
| Proposed Fundraise to raise approximately £... | 26-Mar-2026 | 17:16 | RNS |
| Issue of Equity | 26-Mar-2026 | 16:44 | RNS |
| Phase 1 study opening for AVA6103 | 16-Mar-2026 | 07:00 | RNS |
| Phase 1 study opening for AVA6103 | 16-Mar-2026 | 07:00 | RNS |
| PreCISION payload delivery advantage over ADC | 24-Feb-2026 | 07:00 | RNS |
| Appointment of CSO | 09-Feb-2026 | 07:00 | RNS |
| Faridoxorubicin Program Clinical Updates | 03-Feb-2026 | 07:00 | RNS |
| FDA Clearance of IND Application for AVA6103 | 21-Jan-2026 | 07:00 | RNS |
| Year-end trading update | 20-Jan-2026 | 07:01 | RNS |
| Appointment of Nominated Adviser & TVR | 20-Jan-2026 | 07:00 | RNS |
| Faridoxorubicin Phase 1b SGC data | 17-Dec-2025 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 75.00p |
| Change Today | -4.60p |
| % Change | -5.78 % |
| 52 Week High | 82.50 |
| 52 Week Low | 27.50 |
| Volume | 2,251,371 |
| Shares Issued | 456.29m |
| Market Cap | £342.22m |
| Beta | 0.01 |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 17:11 | 29,861 @ 75.00p |
| 16:35 | 284 @ 75.00p |
| 16:35 | 17 @ 75.00p |
| 16:35 | 223 @ 75.00p |
| 16:35 | 4 @ 75.00p |
You are here: research